| Literature DB >> 27170040 |
Michelle E Wood1,2,3, Laura J Sherrard4,5, Kay A Ramsay4,6, Stephanie T Yerkovich6,7, David W Reid8,9, Timothy J Kidd10,11, Scott C Bell4,8,6.
Abstract
BACKGROUND: People with cystic fibrosis (CF) may work in healthcare settings risking nosocomial pathogen acquisition. The aim of this study was to determine the incidence of methicillin-resistant Staphylococcus aureus (MRSA) infection in adult healthcare workers with CF (HCWcf).Entities:
Keywords: Cystic fibrosis; Employment; Incidence; MRSA; Nosocomial infection
Mesh:
Substances:
Year: 2016 PMID: 27170040 PMCID: PMC4865022 DOI: 10.1186/s12890-016-0243-z
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Fig. 1Cross-sectional observational study design. This study identified patients with CF, who were MRSA culture positive and were either a HCWcf or a non-HCWcf. Abbreviations: HCWcf, adult healthcare workers with CF; non-HCWcf, adult non-healthcare workers with CF; TPCH, The Prince Charles Hospital. *Multiresistant MRSA was detected in 5 HCWcf and 30 non-HCWcf. Non-multiresistant MRSA was detected in 5 HCWcf and 10 non-HCWcf
Demographics and Clinical Characteristics of HCWcf and non-HCWcf
| Characteristics | HCWcf | Non-HCWcf |
| ||
|---|---|---|---|---|---|
| No.a | No.a | ||||
| Age (years), median (IQR) | 21 | 29 (23–37) | 254 | 27 (21–34) | 0.116 |
| FEV1% predicted, median (IQR) | 20 | 72.1 (61.3–90.9) | 239 | 58.5 (37.9–73.1) | 0.003 |
| Number of hospitalisations in previous 2 years, median (IQR) | 19 | 1 (0–3) | 247 | 2 (0–5) | 0.374 |
| Number of hospital days, median (IQR) | 19 | 9 (0–27) | 246 | 16 (0–52) | 0.251 |
| Pancreatic insufficient, | 21 | 16 (76) | 254 | 221 (87) | 0.177 |
|
| 20 | 15 (75) | 255 | 224 (88) | 0.157 |
a21 HCWcf and 255 non-HCWcf included in the analysis. Data missing on some occasions
Regression analysis of factors associated with MRSA acquisition
| Univariable | Odds ratio (95 % CI) |
|
| Healthcare worker | 4.87 (1.95–12.27) | 0.001 |
| Age (per 5 years) | 0.79 (0.65–0.97) | 0.026 |
| FEV1% predicted (per 5 %) | 0.98 (0.91–1.05) | 0.514 |
| Number of hospital admissions in previous 2 years (per admission) | 1.11 (1.01–1.22) | 0.028 |
| Multivariable | Odds ratio (95 % CI) |
|
| Healthcare worker | 8.36 (2.99–23.39) | <0.001 |
| Age (per 5 years) | 0.78 (0.61–0.99) | 0.039 |
| Number of hospital admissions in previous 2 years (per admission) | 1.13 (1.03–1.25) | 0.011 |
Demographics and Clinical Data of MRSA positive patients
| Characteristics | HCWcf | Non-HCWcf |
| ||
|---|---|---|---|---|---|
| No.a | No.a | ||||
| Male, | 10 | 5 (50) | 40 | 25 (63) | 0.494 |
| Age (years), median (IQR) | 10 | 28 (26–37.5) | 39 | 22 (19–27) | 0.02 |
| FEV1 % predicted, median (IQR) | 10 | 72.4 (62.2–90.9) | 36 | 48.7 (33.2–64.8) | 0.009 |
| Pancreatic insufficient, | 10 | 7 (70) | 40 | 38 (95) | 0.048 |
|
| 10 | 7 (70) | 40 | 37 (93) | 0.086 |
| Hospitalisations in 2 years prior, median (IQR) | 9 | 3 (1–4) | 32 | 4 (2–6) | 0.23 |
| Hospital days in 2 years prior, median (IQR) | 9 | 27 (4–37) | 31 | 49 (19–76) | 0.177 |
| Peripheral colonisation, | 9 | 2 (22) | 33 | 9 (27) | 1.0 |
| mrMRSA, | 10 | 5 (50) | 40 | 30 (75) | 0.143 |
Abbreviations: mrMRSA, multiresistant MRSA
a10 HCWcf and 40 non-HCWcf included in this analysis. Data missing on some occasions
Types of infection and treatment outcomes among the 10 adult healthcare workers with CF (HCWcf) and methicillin-resistant Staphylococcus aureus (MRSA) airways infection
| HCWcf ( | Type of infectiona | Antibiotic treatmenta | Outcome | ||||
|---|---|---|---|---|---|---|---|
| Rifampicin | Sodium fusidate | Linezolid | Eradicated | Chronic | Spontaneously cleared | ||
| 1 | Chronic | X | X | X | |||
| 2 | Chronic | X | X | X | |||
| 3 | Chronic | X | X | X | |||
| 4 | Chronic | X | X | X | |||
| 5 | Chronic | X | X | X | |||
| 6b | Chronic | X | X | X | X | ||
| 7c | Intermittent | X | X | X | |||
| 8 | Intermittent | X | |||||
| 9 | Intermittent | X | |||||
| 10 | Intermittent | X | |||||
aMedian (IQR) time to initiation of treatment was 52 (37.5–77) days
bPatient was prescribed 6 weeks of linezolid following 6 months of rifampicin plus sodium fusidate
cPatient commenced eradication treatment but self-elected to cease after 3 weeks of therapy because of intolerance